 CytoSorbents Corporation NASDAQ:CTSO, a critical care immunotherapy leader specializing in blood purification, announces that CytoSorb is now approved and immediately available in the European Union for the removal of rivaroxaban Xarelto- Bayer, JansennJohnson Johnson, a widely-used Factor Xa inhibitor and novel oral anticoagulant NOAC, during cardiothoracic surgery requiring cardiopulmonary bypass CPB. With this announcement, and the E.U. approval earlier this year to remove the P2Y12 anti-platelet inhibitor, ticagrelor, for the same indication, CytoSorb is providing cardiac surgeons and perfusionists an easy-to-use and rapid new treatment option to help reduce the risk of serious and potentially fatal perioperative bleeding complications caused by these two drugs, in separate categories of blood thinners. 